Two posters with the results of completed clinical trials that described CBL0137 safety, pharmacokinetics, and efficacy in patients with advanced solid tumors were presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting which was held on May 29-31, 2020 in the virtual format.
Poster 337 (abstract #3607) described the results of the first-in-human phase 1b dose-escalation study of oral CBL0137 in patients with advanced solid tumors.
Poster 313 (abstract #3583) reported the results of a phase 1 trial of CBL0137 administered intravenously to patients with advanced solid tumors. To view the posters please follow these links: Poster 337 (3607) and Poster 313 (3583). Both abstracts are available in the Meeting Library.